Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANCHOR-2: depemokimab in chronic rhinosinusitis with nasal polyps
jRCT2031220094Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Depemokimab 100 mg SC + standard of care with Placebo SC + standard of care (2 arms). Primary endpoints: Change from baseline in total endoscopic nasal polyp score at Week 52 (centrally read) and Change from baseline in mean nasal obstruction score (VRS) from Week 49 through Week 52. Started Aug 2022; status: completed.
02
Drugs
depemokimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on jRCT2031220094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220094.